










CELL-BASED POTENCY ASSAY TESTING
TAILORED TO MEET GMP REQUIRMENTS

At Svar, we specialize in cutting-edge solutions for MoA reflective potency assays in early drug development and GMP-regulated batch release.

With extensive expertise in establishing and conducting routine bioassays, we offer testing services for drug substances, final products, intermediates, and starting materials for large molecule drug products. Our diverse range of potency assays can be tailored to meet specific requirements.

Explore Our Services:

- MoA Reflective Potency Assays for Early Drug Development and GMP-Regulated Batch Release
- Development and Validation of Methods for Routine Batch Release Testing
- GMP Analysis of Biologics and Biosimilar Samples from Development to Manufacturing

WHY CHOOSE SVAR?

Svar offers a unique combination of scientific expertise, high-quality assay products, strong services, and proprietary technology platforms.

Our approach ensures a flexible, effective, and seamless experience for our customers across different development needs in a way that no other single business can.

Discover how Svar answers to the challenges and opportunities of potency bioassays under GMP conditions!

Svar Life Science AB I Lundavägen 151 I 212 24 Malmö I +46 40 53 76 00 I www.svarlifescience.com

ANSWERING TO YOUR EVERY NEED
BIOLOGICALLY RELEVANT CELL-BASED BIOASSAYS

ENGINEERED CELLS FOR
FUNCTIONAL MOA REFLECTIVE CELL-BASED ASSAYS

Experience Biologically Relevant Cell-Based Bioassays Tailored to Your Specifications:

- Engineered cell lines tailored for challenging bioassays
- Assay ready cells format enabling easy workflow and maximized control
- Custom solutions tailored to your assay development and manufacturing needs

Discover the Benefits of *iLite*® Technology for Ensuring the Success of Your Projects

CELL-BASED REPORTER GENE ASSAYS
FUNCTIONAL CHARACTERIZATION AND POTENCY ASSESSMENT

Supporting the Development of Innovative Therapies from Screening and Characterization to Potency Testing:

- Ready-to-use C3a, C5a, CDC *iLite*® bioassays for evaluating inhibition in complement-targeting therapeutics
- Versatile pathway-specific GLP-1, GIP, Insulin and FGF21 *iLite*® bioassays for MoA-driven evaluation of emerging single- and multi-agonist metabolic therapeutics

TARGETING FC-EFFECTOR & CELL-ACTIVATION FUNCTIONS

A Powerful Way of Measuring the Effector & Activation Functions of Monoclonal Antibodies:

- Fast & efficient evaluation of Fc-γ Receptor induced Cell-Activation
- Highly sensitive ADCC, ADCP, CDC and CD3 *iLite*® reporter gene assays with true MoA-reflecting properties
- Assay ready effector and target cells engineered to work optimally together

Drive Innovation with Cell-Based Reporter Gene Assays



DOWNLOAD CASE STORY

How to Design Potency Assays for Gene Therapy Projects

Discover the intricate process at Svar of designing, constructing, producing, and validating a fit-for-purpose potency assay essential for batch release in AAV-based gene therapy drugs.

This case study provides insight into the development of an advanced potency assay tailored for sophisticated products, such as the reporter-gene assay. Follow the journey from the initial client engagement through the stages of development, validation, and eventual manufacturing of the finished product.

Explore the complexities and solutions involved in crafting a robust potency assay crucial for the success of gene therapy projects.

Doc No: S-127-GB01, Nov 2026

SVAr
Answers in Life Science